STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.

Otros idiomas Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Acciones

300204

CNE100001237

Precio de cierre Shenzhen S.E. Otros sitios de cotización 00:00:00 10/05/2024			Varia. Cinco días.	Varia. 1 de enero.
6,77 ^CNY	-4,38 %		+1,35 %	-33,37 %

24/04	Staidson (Pekín) BioPharmaceuticals Co., Ltd. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
25/03	Staidson (Pekín) BioPharmaceuticals Co., Ltd. presenta los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23
Staidson BioPharmaceuticals Co., Ltd.(XSEC:300204) added to S&P Global BMI Index	18/09/23
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23
Staidson BioPharmaceuticals Co., Ltd. amended terms of the transaction	26/06/23
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23
Staidson Pharma Unit Gets FDA's Emergency Use Authorization for COVID-19 Drug; Shares Soar 18%	06/04/23
Review Into Staidson Biopharma Unit's Anti-COVID-19 Drug Shows Safety, Tolerability in Patients; Shares Jump 5%	17/02/23
Staidson's Respiratory Drug Shows Safety in Trial	23/01/23
Chinese Shares Finish Lower; Staidson Falls 8% After Signing R&D Deal With Germany’s InflaRx	23/12/22
Staidson Forms R&D Deal With Germany’s InflaRx	23/12/22
Staidson BioPharmaceuticals Co., Ltd. announced that it expects to receive CNY 580 million in funding	22/12/22
Inflarx Gmbh and Staidson Biopharmaceuticals Co., Ltd Enters into Third Addendum to the Co-Development Agreement	21/12/22
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19	21/12/22
InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson BioPharmaceuticals Co., Ltd.	21/12/22
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22/08/22
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	18/04/22
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	18/04/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Acciones

300204

CNE100001237

Otros idiomas

Filtros